People · Operator
Named in public records as an officer, director or promoter · active 2015–2025 · Biotechnology, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Iambic Therapeutics, Inc. | — | Biotechnology | Series D+ | $240.9M | $697.8M | 2023 |
| NextPoint Therapeutics, Inc. | — | Biotechnology | Series C | $122.5M | $444.1M | 2024 |
| ManaT Bio, Inc. | — | Biotechnology | Series C | $72.1M | $848.7M | 2023 |
| Haystack Oncology, Inc. | — | Biotechnology | Series C | $67.0M | $1.1B | 2022 |
| eNeura, INC. | — | Other Technology | Series A | $53.6M | $14.2M | 2015 |
| Mind-X Corp. | — | Other Technology | Seed | $2.3M | $59.6M | 2018 |
R. Jacob Vogelstein at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside R. Jacob Vogelstein on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Oros | 2 | 5 |
| George Petrocheilos | 2 | 3 |
| Jack Nielsen | 1 | 13 |
| David Rosen | 1 | 10 |
| Jishnu Bhattacharjee | 1 | 9 |
| Ansbert Gadicke | 1 | 7 |
| Robert Kline | 1 | 6 |
| Robert Fischell | 1 | 6 |
| Kurt Von Emster | 1 | 6 |
| David Fischell | 1 | 6 |
| Paulina Hill | 1 | 5 |
| Thomas Miller | 1 | 5 |
| William Rastetter | 1 | 4 |
| Detlev Biniszkiewicz | 1 | 4 |
| Shalini Sharp | 1 | 4 |
| Isaac Ro | 1 | 4 |
| Raymond Camahort | 1 | 4 |
| Cary G. Pfeffer | 1 | 3 |
| Matthew Roden | 1 | 3 |
| Evan Rachlin | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.